View ValuationTelo Genomics 将来の成長Future 基準チェック /06現在、 Telo Genomicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 03+ 1 more updateTelo Genomics Corp. Announces Board ChangesTelo Genomics Corp. has appointed John Farlinger as its new Chairman. Mr. Farlinger currently serves as the chair of the company's audit committee. In connection with this appointment, the company and Mr. Farlinger have entered into a management consulting agreement. Mr. Farlinger is a seasoned public markets, venture, and private equity-backed executive and entrepreneur, bringing more than 30 years of experience in operations, technology, and finance. Mr. Farlinger is a Chartered Professional Accountant (CPA, CA) and graduated with a Bachelor of Commerce (Hons) from Queen's University. The Company has also announced that Guido Baechler is resigning from his positions as Executive Chairman and director, effective March 31, 2026. While stepping down from the board, Mr. Baechler will remain with the Company in an advisory capacity.お知らせ • Mar 10Telo Genomics Corp. announced that it has received CAD 1.385 million in fundingOn March 9, 2026, Telo Genomics Corp. closed the transaction. The company issued Debentures for gross proceeds of CAD 545,000 in its second and final tranche. The company raised a total of CAD 1,385,000 under the offering. The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the “Maturity Date”). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common share of the Company (each, a “Share”) at a conversion price of CAD 0.05 per Share. The Company has no right to prepay the Debentures prior to the Maturity Date. In connection with the sale of the Debentures, the Company issued to the purchasers one transferable detachable warrant (a “Warrant”) for every CAD of principal amount of the Debentures subscribed for. The Company issued an aggregate of 10,900,000 Warrants in connection with the Second Tranche. Each Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2027. In connection with the Second Tranche, the Company paid cash finder’s fees of CAD 50 and issued 679,000 finder’s warrants (each, a “Finder’s Warrant”). Each Finder’s Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2028. The Debentures, Warrants and Finder’s Warrants issued in connection with the Second Tranche and any securities issuable upon conversion or exercise will be subject to a four month and one day hold period, expiring July 7, 2026 in accordance with applicable Canadian securities laws. The company announced that two subscribers who purchased an aggregate of CAD 00 of Debentures under the Second Tranche are considered to be related parties of the Company (the "Related Party Participation"). Specifically, John Price, the CFO of the Company, subscribed for CAD 00 of Debentures and 200,000 Warrants, and John Farlinger, a director of the Company, subscribed for CAD 35,000 of Debentures and 700,000 Warrants.お知らせ • Jan 30Telo Genomics Corp. Announces Chief Financial Officer ChangesTelo Genomics Corp. announced that John Price has been appointed as Chief Financial Officer, effective January 30, 2026. John Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His prior experience includes executive positions in several public companies including Assure Holdings, National Beverage, Alliance MMA, and MusclePharm. He also held various accounting and finance roles in high growth technology companies in Silicon Valley including Opera Software, GCT Semiconductor and Tessera Technologies. John Price spent the first seven years of his career with Ernst & Young. He earned a Bachelor of Science in Accounting from Pennsylvania State University. John Price succeeds Christopher Ross who has served as the Company's CFO since April 2021.お知らせ • Jan 19Telo Genomics Corp. announced that it expects to receive CAD 1.2 million in fundingTelo Genomics Corp announced a non-brokered private placement to issue secured convertible debentures for aggregate gross proceeds of CAD 1,200,000 on January 19, 2026. The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date. The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company at a conversion price of CAD 0.05 per common share. For every CAD 100,000 of convertible debentures issued, Telo Genomics will issue 2 million Detachable Warrants. Each Warrant will be exercisable to acquire one common share at an exercise price of CAD 0.08 per share for a period of 12 months from the closing date. The Company has no right to prepay the Debentures prior to the Maturity Date. The Debentures, Warrants and any securities issuable upon conversion or exercise will be subject to a four month hold period in accordance with applicable Canadian securities laws.お知らせ • Oct 08Telo Genomics Corp., Annual General Meeting, Dec 10, 2025Telo Genomics Corp., Annual General Meeting, Dec 10, 2025. Location: ontario, toronto Canadaお知らせ • Jun 20Telo Genomics Corp. Initiate Clinical Trial Forimal Residual Disease in Multiple MyelomaTelo Genomics Corp. announced that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay. Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloViewMM-MRD.MRD refers to the small number of remaining cancer cells post treatment. The TeloView MM-MR D test provides industry leading sensitivity for counting MRD cells, which is an established metric in assessing MRD. Critically, the TeloView MM-MRd test also offers the potential to profile the malignancy of individual cancer cells and stratify patients based on the aggressiveness of their remaining MRD. TeloView MM-MRB's proprietary approach of counting and profiling individual MRD cells has the potential to provide important, actionable information to clinicians and provide guidance in decision making, including; the extension of therapy, stopping therapy or resuming therapy, with the potential to improve clinical outcomes for MM patients post treatment. In North America, there are approximately 180,000 MM patients receiving treatment across the spectrum of different stages of the disease. Most of these patients could benefit from ongoing monitoring of treatment response using MRD assessment. Depending on the stage of the disease, patients may be monitored on a quarterly basis, leading to a total addressable market of approximately 800,000 tests per year. While the initial focus is on MM MRD, the collaboration allows for additional research that can validate assays for other utility cases in hematological malignancies, such as TeloView SMM, which is an assay that stratifies patients that are identified as having smoldering MM, a precursor to active MM. About MRD Assessment. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is. expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma. MRD treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.お知らせ • Apr 11Telo Genomics Corp. Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025Telo Genomics Corp. announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView®? Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Telo's ongoing MRD clinical trials with McGill University/Jewish General Hospital have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView®?, to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine. ASCO's 2025 Annual Meeting will take place May 30 - June 3, 2025, in Chicago, Illinois. Founded in 1964, ASCO brings together more than 45,000 oncology professionals worldwide, dedicated to improving cancer care through research, education, and promotion of the highest quality patient care. ASCO is widely considered one of the most prestigious oncology research conferences of the year. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.お知らせ • Mar 12Telo Genomics Corp. Announces Management ChangesTelo Genomics Corp. announced Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working closely with the company's founder Dr. Sabine Mai and with the executive team to further advance Telo Genomics' machine-learning (ML)-driven 3D Telomere platform in oncology, which is currently focused on multiple myeloma and prostate cancer. Mr. Baechler joined Telo Genomics' Board of Directors on February 28, 2019, as an independent director and was appointed Chairman on May 6, 2020. He brings over 30 years of leadership experience in the life sciences and medical diagnostics industries, with a strong track record of driving growth and innovation. Prior to joining Telo Genomics, Mr. Baechler spent nearly two decades at Roche Diagnostics, where he held various senior leadership roles across Europe and North America. His deep expertise in advancing cutting-edge diagnostic technologies and commercializing clinical solutions positions him well, to help guide Telo Genomics through its next phase of growth and commercialization. The Company also reports that the consulting arrangement with Sherif Louis, the former President of the Company, has not been renewed. Mr. Louis' duties will be assumed on an interim basis by members of the senior management team under the guidance of Mr. Baechler.お知らせ • Dec 24Telo Genomics Corp. announced that it has received CAD 2.5459 million in fundingOn December 23, 2024. Telo Genomics Corp. has closed the transaction. it has issued 25,459,000 units at a price of CAD 0.10 per Unit for gross proceeds of CAD 2,545,900. In connection with the Offering, the Company paid a total of CAD 164,913 cash and issued a total of 1,649,130 finder's warrants as finder's fees to eligible arm's length finders. Each Finder's Warrant entitles the holder to acquire one Common Share at a price of CAD 0.10 per Common Share until December 23, 2025. A director of the Company acquired 150,000 Units in the Private Placement. The director's participation is considered to be a related party transaction as defined under Multilateral Instrument 61-101お知らせ • Dec 12Telo Genomics Corp. announced that it expects to receive CAD 2 million in fundingTelo Genomics Corp. announced a non-brokered private placement of 20,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 2,000,000 on December 12, 2024. Each unit will consist of one common share of the Company and one nontransferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the closing date of the Offering, subject to acceleration. n connection with the Offering, the Company may pay finder's fees to eligible arm's length parties. The finder's fees may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.お知らせ • Oct 22Telo Genomics Corp. Presents New Performance Data for Its Smoldering Myeloma Prognostic TestTelo Genomics Corp. announced that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma Society (IMS) 2024 annual meeting 2024 in Brazil. The new data was based on a comparative analysis between TeloViewSMM's results and the 20-2-20 scoring model, which is currently included in the smoldering myeloma prognostic international guidelines. The TeloViewSMM prog prognostic test outperformed the 20-2-20 score in identifying both true positive (high risk patients) and true negative (low risk patients). The analysis was conducted on the same cohort of 160 SMM patients. The presented results supersede the performance of all historic attempts to stratify SMM patients to their respective risk of progression to full stage multiple myeloma and presents a viable prognostic product with high sensitivity and specificity to stratify the SMM patients. The results of this analysis were presented in an important discussion session in the IMS 2024 program by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, and Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies. The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients. High risk SMM patients may benefit from immediate treatment intervention, with a possibility to achieve cure due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw. Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated 0.5% of the population over 40 years old being affected, which implies that the total TeloViewSMM addressable market could result in over 500,000 tests per year.お知らせ • Sep 25Telo Genomics Corp., Annual General Meeting, Nov 27, 2024Telo Genomics Corp., Annual General Meeting, Nov 27, 2024. Location: ontario, toronto Canadaお知らせ • Sep 11Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation StudyTelo Genomics Corp. announced that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada. Telo will utilize clonoSEQ® assay technology to validate the sensitivity of its MRD assay and help to establish the clinical utility of TELO-DMRD for MRD enumeration. McGill is participating in the development of two MRD assessment prognostic tests with Telo Genomics. Telo's announced MRD evaluation study conducted with Adaptive Biotechnologies is planned to include up to ten patients that will be followed up over time. The study is open to expansion based on initial results. The first patient samples have already been analyzed. Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine.お知らせ • Jun 13Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic TestsTelo Genomics Corp. announced that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30, 2024 to June 4, 2024. The presented results described the validation and release of Telo's proprietary tool, CellSelect-Pro, that was developed using machine learning and AI platforms, to facilitate high throughput processing of samples while enhancing consistency and accuracy. The tool will favorably impact the sample processing turn-around-time (TAT) with potential cost savings of 20%-25% versus manual cell selection in the company's TeloView myeloma diagnostic tests. The innovative, proprietary algorithm was developed to identify, quantify and process myeloma plasma cells found in the patients' samples being tested. Over 5,000 myeloma positive and negative cells were used to train the AI algorithm, which was validated by processing over 20 myeloma patients' samples. CellSelect-Pro achieved accuracy of >90% and percision of >80% in the conducted validation. The tool was successfully implemented into Telo's testing workflows. The primary clinical application for CellSelect-Pro is Telo's product for smoldering multiple myeloma (SMM) patients, TeloViewSMM, offered now in the USA through the Company's SMART program (Smoldering Multiple myeloma Assessment of Risk for Transformation). CellSelect-Pro was also implemented in the workflow of Telo's active MRD (Minimal Residual Disease) clinical trial for treated multiple myeloma patients, conducted in collaboration with the McGill University, Montreal, Canada.お知らせ • Jun 06Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in fundinga non-brokered private placement to issue 3,000,000 units at an issue price of CAD 0.20 per unit for the gross proceeds of CAD 600,000 on June 4, 2024. Each Unit will consist of one common share and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 36 months from the closing date of the Offering. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.20 per Common Share for a period of 12 months from the closing date of the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month and one day hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.お知らせ • Dec 09Telo Genomics Corp. Announces Executive ChangesTelo Genomics Corp. announced that Kris Weinberg has stepped down as the Chief Executive Officer ("CEO") of the Company. In connection with Mr. Weinberg's resignation, Telo Genomics announced that it has appointed Dr. Sabine Mai as the Company's interim CEO. Dr. Mai founded the Company, created Telo Genomics' proprietary technology, and has acted as a director of the Company since 2016. Dr. Mai is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, as well as a Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science at the University of Manitoba. Dr. Mai is also a director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba.お知らせ • Oct 19Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone AchievedTelo Genomics Corp. announced the launch of its TeloViewSMM to clinicians in the United States. Combining molecular biology and artificial intelligence, the diagnostic platform performs 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes. TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and therefore predict their progression. The Company's initial clinical launch will focus on testing for "Smoldering Multiple Myeloma (SMM)" the precursor for Multiple Myeloma, a blood-based bone marrow cancer. Approximately 50% of patients with SMM will develop full Multiple Myeloma. The test is available for physicians to order under the SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) protocol, an observational study intended for oncology/hematology physicians and their staff in the U.S., to gain experience ordering and utilizing the TeloViewSMM assay. SMART follows a positive industry trend toward introducing novel molecular testing tools in an observational construct to efficiently gather information and feedback from clinicians and their teams. While the initial launch of TeloViewSMM will be conducted as a single-site CLIA (Clinical Laboratory Improvement Amendments) model, commercial-scale delivery of testing will be accomplished in partnership with large reference labs where FISH and microscopy resources are available and scalable. The company is also developing products and use cases for the biopharma and CRO segment and has an active business development pipeline focused on CDx opportunities and contract research.お知らせ • Oct 13Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual MeetingTelo Genomics Corp. announced that it has participated in the International Myeloma Society (‘IMS’) annual meeting that took place in Athens, Greece during the last week of September 2023. The company presented positive results in assessing minimal residual disease (‘MRD’) in multiple myeloma (‘MM’). The data presented demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice. The presented results will be published in the journal of Clinical Lymphoma, Myeloma & Leukemia. Telo's MRD test pioneers an innovative, proprietary and minimally invasive technology with the potential to facilitate MRD assessment in most MM patients. The test is designed to monitor MM patients' performance post-treatment to predict patients' relapse or to guide an informed decision to terminate maintenance therapy for patients who remain in remission, a critical unmet need in the clinic. The data presented at the IMS meeting represents the initial phase of an ongoing prospective clinical trial to monitor disease progression in post-treatment patients, by measuring and profiling MRD in these patients using Telo's proprietary technology. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada.お知らせ • Sep 26Telo Genomics Corp., Annual General Meeting, Nov 30, 2023Telo Genomics Corp., Annual General Meeting, Nov 30, 2023.お知らせ • Jun 16Telo Genomics Corp. announced that it has received CAD 2.833875 million in fundingJune 14, 2023, Telo Genomics Corp. closed the transaction. The company issued 11,335,500 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,833,875. The warrants will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share until June 13, 2025. The company paid a total of CAD 173,503.75 finder's fees in cash and issued a total of 694,015 finder's warrants. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of CAD 0.25 per share until June 13, 2024. The securities issued pursuant to the Offering are subject to a statutory four month hold period ending on October 14, 2023 in accordance with applicable securities laws.お知らせ • Jun 13Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023Telo Genomics Corp. presented the results of its latest study on June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the utility of the TeloView technology to identify newly diagnosed multiple myeloma (NDMM) patients with a high-risk to relapse within 1 year while receiving first-line therapy. In this 174-patient study, the TeloView MM assay was used to predict the outcome of patients in 2 cohorts. Cohort 1 exclusively included patients who relapsed within 1 year of initiating first line therapy. Cohort 2 was made up of patients that responded to therapy and had stable disease for over 3 years after starting therapy. The TeloView MM assay proved to be a powerful predictive tool in both groups, achieving combined accuracy of over 80%. Predicting NDMM patient response to first line therapy is a critical unmet clinical need. In current clinical practice, patients will remain on a specific treatment regimen until relapse and then be switched to an alternative regimen. The cost of therapy can range between $100,000 - 150,000 per year and most NDMM patients do relapse on first line therapy within 24 months. TeloView-MM testing for the newly diagnosed population has the potential to allow treating physicians to make informed decisions to switch high-risk patients to an alternative treatment proactively and avoid the relapse event. The TeloView-MM assay has the potential to benefit over 35,000 NDMM patients annually in the US with a total addressable market of approximately 300,000 tests per year.お知らせ • May 20Telo Genomics Corp. announced that it expects to receive CAD 2 million in fundingTelo Genomics Corp. announced a non-brokered private placement of 8,000,000 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,000,000 on May 19, 2023. Each Unit will consist of one common share of the Company and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 24 months from the date of issuance. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.25 per Common Share for a period of 12 months from the date of issuance. The securities issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.お知らせ • May 06Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology CongressTelo Genomics Corp. announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract summarizes the results to date of the second clinical study that Telo is conducting in collaboration with the Mayo Clinic. The study's objective is to validate the utility of TeloView technology in identifying newly diagnosed multiple myeloma (NDMM) patients, who might develop resistance to first line therapy within 12 months from the point of diagnosis. The study also aims to confirm multiple myeloma (MM) disease stability for patients who go into remission. This important subgroup may have a low probability to relapse for up to 3 years, over which time they can monitored with TeloView. The results summarized in the abstract are under embargo until the abstract is published online on the EHA website on May 11, 2023. Acceptance of the NDMM study data for presentation and publication at EHA 2023 highlights Telo's successful path in establishing TeloView technology as an important predictive/prognostic tool in the management of MM across several stages of the disease. Telo has recently announced that the results of its smoldering multiple myeloma (SMM) clinical study, also conducted in collaboration with the Mayo Clinic, were accepted for presentation and publication at the American Society for Clinical Oncology (ASCO) 2023 annual meeting, to be held from June 2-6th, 2023. Telo's lead product is designed to identify high-risk SMM patients who may receive earlier treatment intervention before the patient develops symptoms from active MM. Notably, the test will also benefit the larger subset of low-risk SMM patients, who have a more stable form of the disease, and do not require immediate treatment. These patients can be regularly monitored using Telo's test, importantly, stable SMM patients may be tested up to every three months. The Company's second assay is designed to identify NDMM patients who are most likely to develop treatment resistance and relapse earlier than expected. Identifying these patients will enable physicians to modify treatment regimens in real time. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important unmet clinical need in the treatment of MM. The total addressable market for both of Telo's MM assays is over 750,000 tests per year in the US. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Telo Genomics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:TDSG.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025N/A-3-2-2N/A9/30/2025N/A-3-2-2N/A6/30/2025N/A-3-2-2N/A3/31/2025N/A-3-2-2N/A12/31/2024N/A-2-2-2N/A9/30/2024N/A-3-2-2N/A6/30/2024N/A-3-2-2N/A3/31/2024N/A-3-3-3N/A12/31/2023N/A-3-3-3N/A9/30/2023N/A-3-3-3N/A6/30/2023N/A-3-3-3N/A3/31/2023N/A-3-2-2N/A12/31/2022N/A-2-2-2N/A9/30/2022N/A-2-2-2N/A6/30/2022N/A-2-2-2N/A3/31/2022N/A-2-2-2N/A12/31/2021N/A-2-2-2N/A9/30/2021N/A-1-1-1N/A6/30/2021N/A-1-1-1N/A3/31/2021N/A-1-1-1N/A12/31/2020N/A-1-1-1N/A9/30/2020N/A-1-1-1N/A6/30/2020N/A-1-1-1N/A3/31/2020N/A-1-1-1N/A12/31/2019N/A-100N/A9/30/2019N/A-1N/A0N/A6/30/2019N/A-1N/A0N/A12/31/2018N/A-3N/A-2N/A9/30/2018N/A-4N/A-2N/A6/30/2018N/A-5N/A-3N/A3/31/2018N/A-6N/A-4N/A12/31/2017N/A-8N/A-5N/A9/30/2017N/A-8N/A-6N/A6/30/2017N/A-10N/A-8N/A3/31/2017N/A-8N/A-7N/A12/31/2016N/A-6N/A-5N/A9/30/2016N/A-5N/A-4N/A6/30/2016N/A-2N/A-1N/A3/31/2016N/A-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TDSG.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: TDSG.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: TDSG.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: TDSG.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: TDSG.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TDSG.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 07:07終値2026/05/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Telo Genomics Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 03+ 1 more updateTelo Genomics Corp. Announces Board ChangesTelo Genomics Corp. has appointed John Farlinger as its new Chairman. Mr. Farlinger currently serves as the chair of the company's audit committee. In connection with this appointment, the company and Mr. Farlinger have entered into a management consulting agreement. Mr. Farlinger is a seasoned public markets, venture, and private equity-backed executive and entrepreneur, bringing more than 30 years of experience in operations, technology, and finance. Mr. Farlinger is a Chartered Professional Accountant (CPA, CA) and graduated with a Bachelor of Commerce (Hons) from Queen's University. The Company has also announced that Guido Baechler is resigning from his positions as Executive Chairman and director, effective March 31, 2026. While stepping down from the board, Mr. Baechler will remain with the Company in an advisory capacity.
お知らせ • Mar 10Telo Genomics Corp. announced that it has received CAD 1.385 million in fundingOn March 9, 2026, Telo Genomics Corp. closed the transaction. The company issued Debentures for gross proceeds of CAD 545,000 in its second and final tranche. The company raised a total of CAD 1,385,000 under the offering. The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the “Maturity Date”). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common share of the Company (each, a “Share”) at a conversion price of CAD 0.05 per Share. The Company has no right to prepay the Debentures prior to the Maturity Date. In connection with the sale of the Debentures, the Company issued to the purchasers one transferable detachable warrant (a “Warrant”) for every CAD of principal amount of the Debentures subscribed for. The Company issued an aggregate of 10,900,000 Warrants in connection with the Second Tranche. Each Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2027. In connection with the Second Tranche, the Company paid cash finder’s fees of CAD 50 and issued 679,000 finder’s warrants (each, a “Finder’s Warrant”). Each Finder’s Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2028. The Debentures, Warrants and Finder’s Warrants issued in connection with the Second Tranche and any securities issuable upon conversion or exercise will be subject to a four month and one day hold period, expiring July 7, 2026 in accordance with applicable Canadian securities laws. The company announced that two subscribers who purchased an aggregate of CAD 00 of Debentures under the Second Tranche are considered to be related parties of the Company (the "Related Party Participation"). Specifically, John Price, the CFO of the Company, subscribed for CAD 00 of Debentures and 200,000 Warrants, and John Farlinger, a director of the Company, subscribed for CAD 35,000 of Debentures and 700,000 Warrants.
お知らせ • Jan 30Telo Genomics Corp. Announces Chief Financial Officer ChangesTelo Genomics Corp. announced that John Price has been appointed as Chief Financial Officer, effective January 30, 2026. John Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His prior experience includes executive positions in several public companies including Assure Holdings, National Beverage, Alliance MMA, and MusclePharm. He also held various accounting and finance roles in high growth technology companies in Silicon Valley including Opera Software, GCT Semiconductor and Tessera Technologies. John Price spent the first seven years of his career with Ernst & Young. He earned a Bachelor of Science in Accounting from Pennsylvania State University. John Price succeeds Christopher Ross who has served as the Company's CFO since April 2021.
お知らせ • Jan 19Telo Genomics Corp. announced that it expects to receive CAD 1.2 million in fundingTelo Genomics Corp announced a non-brokered private placement to issue secured convertible debentures for aggregate gross proceeds of CAD 1,200,000 on January 19, 2026. The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date. The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company at a conversion price of CAD 0.05 per common share. For every CAD 100,000 of convertible debentures issued, Telo Genomics will issue 2 million Detachable Warrants. Each Warrant will be exercisable to acquire one common share at an exercise price of CAD 0.08 per share for a period of 12 months from the closing date. The Company has no right to prepay the Debentures prior to the Maturity Date. The Debentures, Warrants and any securities issuable upon conversion or exercise will be subject to a four month hold period in accordance with applicable Canadian securities laws.
お知らせ • Oct 08Telo Genomics Corp., Annual General Meeting, Dec 10, 2025Telo Genomics Corp., Annual General Meeting, Dec 10, 2025. Location: ontario, toronto Canada
お知らせ • Jun 20Telo Genomics Corp. Initiate Clinical Trial Forimal Residual Disease in Multiple MyelomaTelo Genomics Corp. announced that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay. Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloViewMM-MRD.MRD refers to the small number of remaining cancer cells post treatment. The TeloView MM-MR D test provides industry leading sensitivity for counting MRD cells, which is an established metric in assessing MRD. Critically, the TeloView MM-MRd test also offers the potential to profile the malignancy of individual cancer cells and stratify patients based on the aggressiveness of their remaining MRD. TeloView MM-MRB's proprietary approach of counting and profiling individual MRD cells has the potential to provide important, actionable information to clinicians and provide guidance in decision making, including; the extension of therapy, stopping therapy or resuming therapy, with the potential to improve clinical outcomes for MM patients post treatment. In North America, there are approximately 180,000 MM patients receiving treatment across the spectrum of different stages of the disease. Most of these patients could benefit from ongoing monitoring of treatment response using MRD assessment. Depending on the stage of the disease, patients may be monitored on a quarterly basis, leading to a total addressable market of approximately 800,000 tests per year. While the initial focus is on MM MRD, the collaboration allows for additional research that can validate assays for other utility cases in hematological malignancies, such as TeloView SMM, which is an assay that stratifies patients that are identified as having smoldering MM, a precursor to active MM. About MRD Assessment. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is. expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma. MRD treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.
お知らせ • Apr 11Telo Genomics Corp. Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025Telo Genomics Corp. announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView®? Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Telo's ongoing MRD clinical trials with McGill University/Jewish General Hospital have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView®?, to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine. ASCO's 2025 Annual Meeting will take place May 30 - June 3, 2025, in Chicago, Illinois. Founded in 1964, ASCO brings together more than 45,000 oncology professionals worldwide, dedicated to improving cancer care through research, education, and promotion of the highest quality patient care. ASCO is widely considered one of the most prestigious oncology research conferences of the year. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.
お知らせ • Mar 12Telo Genomics Corp. Announces Management ChangesTelo Genomics Corp. announced Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working closely with the company's founder Dr. Sabine Mai and with the executive team to further advance Telo Genomics' machine-learning (ML)-driven 3D Telomere platform in oncology, which is currently focused on multiple myeloma and prostate cancer. Mr. Baechler joined Telo Genomics' Board of Directors on February 28, 2019, as an independent director and was appointed Chairman on May 6, 2020. He brings over 30 years of leadership experience in the life sciences and medical diagnostics industries, with a strong track record of driving growth and innovation. Prior to joining Telo Genomics, Mr. Baechler spent nearly two decades at Roche Diagnostics, where he held various senior leadership roles across Europe and North America. His deep expertise in advancing cutting-edge diagnostic technologies and commercializing clinical solutions positions him well, to help guide Telo Genomics through its next phase of growth and commercialization. The Company also reports that the consulting arrangement with Sherif Louis, the former President of the Company, has not been renewed. Mr. Louis' duties will be assumed on an interim basis by members of the senior management team under the guidance of Mr. Baechler.
お知らせ • Dec 24Telo Genomics Corp. announced that it has received CAD 2.5459 million in fundingOn December 23, 2024. Telo Genomics Corp. has closed the transaction. it has issued 25,459,000 units at a price of CAD 0.10 per Unit for gross proceeds of CAD 2,545,900. In connection with the Offering, the Company paid a total of CAD 164,913 cash and issued a total of 1,649,130 finder's warrants as finder's fees to eligible arm's length finders. Each Finder's Warrant entitles the holder to acquire one Common Share at a price of CAD 0.10 per Common Share until December 23, 2025. A director of the Company acquired 150,000 Units in the Private Placement. The director's participation is considered to be a related party transaction as defined under Multilateral Instrument 61-101
お知らせ • Dec 12Telo Genomics Corp. announced that it expects to receive CAD 2 million in fundingTelo Genomics Corp. announced a non-brokered private placement of 20,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 2,000,000 on December 12, 2024. Each unit will consist of one common share of the Company and one nontransferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the closing date of the Offering, subject to acceleration. n connection with the Offering, the Company may pay finder's fees to eligible arm's length parties. The finder's fees may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.
お知らせ • Oct 22Telo Genomics Corp. Presents New Performance Data for Its Smoldering Myeloma Prognostic TestTelo Genomics Corp. announced that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma Society (IMS) 2024 annual meeting 2024 in Brazil. The new data was based on a comparative analysis between TeloViewSMM's results and the 20-2-20 scoring model, which is currently included in the smoldering myeloma prognostic international guidelines. The TeloViewSMM prog prognostic test outperformed the 20-2-20 score in identifying both true positive (high risk patients) and true negative (low risk patients). The analysis was conducted on the same cohort of 160 SMM patients. The presented results supersede the performance of all historic attempts to stratify SMM patients to their respective risk of progression to full stage multiple myeloma and presents a viable prognostic product with high sensitivity and specificity to stratify the SMM patients. The results of this analysis were presented in an important discussion session in the IMS 2024 program by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, and Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies. The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients. High risk SMM patients may benefit from immediate treatment intervention, with a possibility to achieve cure due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw. Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated 0.5% of the population over 40 years old being affected, which implies that the total TeloViewSMM addressable market could result in over 500,000 tests per year.
お知らせ • Sep 25Telo Genomics Corp., Annual General Meeting, Nov 27, 2024Telo Genomics Corp., Annual General Meeting, Nov 27, 2024. Location: ontario, toronto Canada
お知らせ • Sep 11Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation StudyTelo Genomics Corp. announced that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada. Telo will utilize clonoSEQ® assay technology to validate the sensitivity of its MRD assay and help to establish the clinical utility of TELO-DMRD for MRD enumeration. McGill is participating in the development of two MRD assessment prognostic tests with Telo Genomics. Telo's announced MRD evaluation study conducted with Adaptive Biotechnologies is planned to include up to ten patients that will be followed up over time. The study is open to expansion based on initial results. The first patient samples have already been analyzed. Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine.
お知らせ • Jun 13Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic TestsTelo Genomics Corp. announced that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30, 2024 to June 4, 2024. The presented results described the validation and release of Telo's proprietary tool, CellSelect-Pro, that was developed using machine learning and AI platforms, to facilitate high throughput processing of samples while enhancing consistency and accuracy. The tool will favorably impact the sample processing turn-around-time (TAT) with potential cost savings of 20%-25% versus manual cell selection in the company's TeloView myeloma diagnostic tests. The innovative, proprietary algorithm was developed to identify, quantify and process myeloma plasma cells found in the patients' samples being tested. Over 5,000 myeloma positive and negative cells were used to train the AI algorithm, which was validated by processing over 20 myeloma patients' samples. CellSelect-Pro achieved accuracy of >90% and percision of >80% in the conducted validation. The tool was successfully implemented into Telo's testing workflows. The primary clinical application for CellSelect-Pro is Telo's product for smoldering multiple myeloma (SMM) patients, TeloViewSMM, offered now in the USA through the Company's SMART program (Smoldering Multiple myeloma Assessment of Risk for Transformation). CellSelect-Pro was also implemented in the workflow of Telo's active MRD (Minimal Residual Disease) clinical trial for treated multiple myeloma patients, conducted in collaboration with the McGill University, Montreal, Canada.
お知らせ • Jun 06Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in fundinga non-brokered private placement to issue 3,000,000 units at an issue price of CAD 0.20 per unit for the gross proceeds of CAD 600,000 on June 4, 2024. Each Unit will consist of one common share and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 36 months from the closing date of the Offering. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.20 per Common Share for a period of 12 months from the closing date of the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month and one day hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.
お知らせ • Dec 09Telo Genomics Corp. Announces Executive ChangesTelo Genomics Corp. announced that Kris Weinberg has stepped down as the Chief Executive Officer ("CEO") of the Company. In connection with Mr. Weinberg's resignation, Telo Genomics announced that it has appointed Dr. Sabine Mai as the Company's interim CEO. Dr. Mai founded the Company, created Telo Genomics' proprietary technology, and has acted as a director of the Company since 2016. Dr. Mai is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, as well as a Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science at the University of Manitoba. Dr. Mai is also a director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba.
お知らせ • Oct 19Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone AchievedTelo Genomics Corp. announced the launch of its TeloViewSMM to clinicians in the United States. Combining molecular biology and artificial intelligence, the diagnostic platform performs 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes. TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and therefore predict their progression. The Company's initial clinical launch will focus on testing for "Smoldering Multiple Myeloma (SMM)" the precursor for Multiple Myeloma, a blood-based bone marrow cancer. Approximately 50% of patients with SMM will develop full Multiple Myeloma. The test is available for physicians to order under the SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) protocol, an observational study intended for oncology/hematology physicians and their staff in the U.S., to gain experience ordering and utilizing the TeloViewSMM assay. SMART follows a positive industry trend toward introducing novel molecular testing tools in an observational construct to efficiently gather information and feedback from clinicians and their teams. While the initial launch of TeloViewSMM will be conducted as a single-site CLIA (Clinical Laboratory Improvement Amendments) model, commercial-scale delivery of testing will be accomplished in partnership with large reference labs where FISH and microscopy resources are available and scalable. The company is also developing products and use cases for the biopharma and CRO segment and has an active business development pipeline focused on CDx opportunities and contract research.
お知らせ • Oct 13Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual MeetingTelo Genomics Corp. announced that it has participated in the International Myeloma Society (‘IMS’) annual meeting that took place in Athens, Greece during the last week of September 2023. The company presented positive results in assessing minimal residual disease (‘MRD’) in multiple myeloma (‘MM’). The data presented demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice. The presented results will be published in the journal of Clinical Lymphoma, Myeloma & Leukemia. Telo's MRD test pioneers an innovative, proprietary and minimally invasive technology with the potential to facilitate MRD assessment in most MM patients. The test is designed to monitor MM patients' performance post-treatment to predict patients' relapse or to guide an informed decision to terminate maintenance therapy for patients who remain in remission, a critical unmet need in the clinic. The data presented at the IMS meeting represents the initial phase of an ongoing prospective clinical trial to monitor disease progression in post-treatment patients, by measuring and profiling MRD in these patients using Telo's proprietary technology. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada.
お知らせ • Sep 26Telo Genomics Corp., Annual General Meeting, Nov 30, 2023Telo Genomics Corp., Annual General Meeting, Nov 30, 2023.
お知らせ • Jun 16Telo Genomics Corp. announced that it has received CAD 2.833875 million in fundingJune 14, 2023, Telo Genomics Corp. closed the transaction. The company issued 11,335,500 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,833,875. The warrants will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share until June 13, 2025. The company paid a total of CAD 173,503.75 finder's fees in cash and issued a total of 694,015 finder's warrants. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of CAD 0.25 per share until June 13, 2024. The securities issued pursuant to the Offering are subject to a statutory four month hold period ending on October 14, 2023 in accordance with applicable securities laws.
お知らせ • Jun 13Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023Telo Genomics Corp. presented the results of its latest study on June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the utility of the TeloView technology to identify newly diagnosed multiple myeloma (NDMM) patients with a high-risk to relapse within 1 year while receiving first-line therapy. In this 174-patient study, the TeloView MM assay was used to predict the outcome of patients in 2 cohorts. Cohort 1 exclusively included patients who relapsed within 1 year of initiating first line therapy. Cohort 2 was made up of patients that responded to therapy and had stable disease for over 3 years after starting therapy. The TeloView MM assay proved to be a powerful predictive tool in both groups, achieving combined accuracy of over 80%. Predicting NDMM patient response to first line therapy is a critical unmet clinical need. In current clinical practice, patients will remain on a specific treatment regimen until relapse and then be switched to an alternative regimen. The cost of therapy can range between $100,000 - 150,000 per year and most NDMM patients do relapse on first line therapy within 24 months. TeloView-MM testing for the newly diagnosed population has the potential to allow treating physicians to make informed decisions to switch high-risk patients to an alternative treatment proactively and avoid the relapse event. The TeloView-MM assay has the potential to benefit over 35,000 NDMM patients annually in the US with a total addressable market of approximately 300,000 tests per year.
お知らせ • May 20Telo Genomics Corp. announced that it expects to receive CAD 2 million in fundingTelo Genomics Corp. announced a non-brokered private placement of 8,000,000 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,000,000 on May 19, 2023. Each Unit will consist of one common share of the Company and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 24 months from the date of issuance. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.25 per Common Share for a period of 12 months from the date of issuance. The securities issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.
お知らせ • May 06Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology CongressTelo Genomics Corp. announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract summarizes the results to date of the second clinical study that Telo is conducting in collaboration with the Mayo Clinic. The study's objective is to validate the utility of TeloView technology in identifying newly diagnosed multiple myeloma (NDMM) patients, who might develop resistance to first line therapy within 12 months from the point of diagnosis. The study also aims to confirm multiple myeloma (MM) disease stability for patients who go into remission. This important subgroup may have a low probability to relapse for up to 3 years, over which time they can monitored with TeloView. The results summarized in the abstract are under embargo until the abstract is published online on the EHA website on May 11, 2023. Acceptance of the NDMM study data for presentation and publication at EHA 2023 highlights Telo's successful path in establishing TeloView technology as an important predictive/prognostic tool in the management of MM across several stages of the disease. Telo has recently announced that the results of its smoldering multiple myeloma (SMM) clinical study, also conducted in collaboration with the Mayo Clinic, were accepted for presentation and publication at the American Society for Clinical Oncology (ASCO) 2023 annual meeting, to be held from June 2-6th, 2023. Telo's lead product is designed to identify high-risk SMM patients who may receive earlier treatment intervention before the patient develops symptoms from active MM. Notably, the test will also benefit the larger subset of low-risk SMM patients, who have a more stable form of the disease, and do not require immediate treatment. These patients can be regularly monitored using Telo's test, importantly, stable SMM patients may be tested up to every three months. The Company's second assay is designed to identify NDMM patients who are most likely to develop treatment resistance and relapse earlier than expected. Identifying these patients will enable physicians to modify treatment regimens in real time. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important unmet clinical need in the treatment of MM. The total addressable market for both of Telo's MM assays is over 750,000 tests per year in the US.